Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study:: The role of EBV shedding

被引:20
作者
Pitt, J
Schluchter, M
Jenson, H
Kovacs, A
LaRussa, P
McIntosh, K
Boyer, P
Cooper, E
Goldfarb, J
Hammill, H
Hodes, D
Peavy, H
Sperling, R
Tuomala, R
Shearer, W
机构
[1] Columbia Univ Coll Phys & Surg, Dept Pediat, Div Infect Dis, New York, NY 10032 USA
[2] Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA
[3] Univ Texas, Hlth Sci Ctr, San Antonio, TX USA
[4] Univ So Calif, Sch Med, LAC USC Med Ctr, Div Pediat Infect Dis, Los Angeles, CA USA
[5] Boston City Hosp, Dept Pediat Infect Dis, Boston, MA 02118 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA
[8] Cleveland Clin Fdn, Div Pediat & Adolescent Med, Cleveland, OH 44195 USA
[9] Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA
[10] Mt Sinai Sch Med, Dept Pediat, New York, NY USA
[11] NHLBI, Div Lung Dis, Bethesda, MD 20892 USA
[12] Mt Sinai Sch Med, Dept Obstet & Gynecol, New York, NY USA
[13] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA
[14] Texas Childrens Hosp, Baylor Coll Med, Dept Allergy & Immunol, Houston, TX 77030 USA
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1998年 / 19卷 / 05期
关键词
HIV-1 maternal-infant transmission; EBV and CMV infection; duration of ruptured membranes;
D O I
10.1097/00042560-199812150-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The association of maternal and perinatal factors with mother-infant transmission of HIV-1 was examined in a prospective multicenter cohort of singleton Live births to 508 HIV-1-infected women with children of known HIV-1 infection status (91 [18%] HIV-1-infected, 417 [82%] uninfected). From multivariate logistic regression, independent predictors of HIV-1 transmission included maternal CD4 percentage (CD4%) (odds ratio [OR] per 10% increase in CD4% = 0.70; p =.003), ruptured membranes <24 hours (OR = 3.15; p =.02), and maternal bleeding (OR = 2.90; p =.03), whereas maternal zidovudine (ZDV) use was marginally associated (OR = 0.60; p =.08). The associations of maternal urinary cytomegalovirus (CMV) shedding, oropharyngeal Epstein-Barr virus (EBV) shedding, and serology profiles during pregnancy with HIV-1 transmission were examined in the subset of mothers in whom the CMV and EBV measurements were available. Maternal EBV seropositivity, CMV shedding, and CMV seropositivity were 100% (279 of 279), 7% (16 of 229), and 92% (270 of 274), respectively. These rates did not differ between transmitting and nontransmitting mothers. In univariate analyses, maternal EBV shedding was higher among transmitting than nontransmitting mothers (40 of 49 [82%] compared with 154 of 226 [68%]; p =.06) and was independently associated with transmission in multivariate logistic analyses adjusting for CD4%, ruptured membranes, and ZDV use, with an OR of 2.45 (95% confidence interval (CI), 1.03-5.84; p =.04). This permits the conclusion that EBV shedding is associated with maternal-infant HIV-1 transmission, independent of CD4%.
引用
收藏
页码:462 / 470
页数:9
相关论文
共 27 条
[1]   TESTS FOR LINEAR TRENDS IN PROPORTIONS AND FREQUENCIES [J].
ARMITAGE, P .
BIOMETRICS, 1955, 11 (03) :375-386
[2]   EFFECTS OF HUMAN-IMMUNODEFICIENCY-VIRUS ON THE CELLULAR IMMUNE-RESPONSE TO EPSTEIN-BARR-VIRUS IN HOMOSEXUAL MEN - CHARACTERIZATION OF THE CYTOTOXIC RESPONSE AND LYMPHOKINE PRODUCTION [J].
BLUMBERG, RS ;
PARADIS, T ;
BYINGTON, R ;
HENLE, W ;
HIRSCH, MS ;
SCHOOLEY, RT .
JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (05) :877-890
[3]  
BOURGAULT I, 1991, CLIN EXP IMMUNOL, V84, P501
[4]   GUIDELINE FOR FLOW CYTOMETRIC IMMUNOPHENOTYPING - A REPORT FROM THE NATIONAL-INSTITUTE-OF-ALLERGY-AND-INFECTIOUS-DISEASES, DIVISION OF AIDS [J].
CALVELLI, T ;
DENNY, TN ;
PAXTON, H ;
GELMAN, R ;
KAGAN, J .
CYTOMETRY, 1993, 14 (07) :702-715
[5]  
CHANG R S, 1973, New England Journal of Medicine, V289, P1325, DOI 10.1056/NEJM197312202892501
[6]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[7]   After AIDS clinical trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants [J].
Cooper, ER ;
Nugent, RP ;
Diaz, C ;
Pitt, J ;
Hanson, C ;
Kalish, LA ;
Mendez, H ;
Zorrilla, C ;
Hershow, R ;
Moye, J ;
Smeriglio, V ;
Fowler, MG ;
Rich, K ;
Turpin, D ;
PachecoAcosta, E ;
Tuomala, R ;
Mesthene, D ;
Fox, H ;
Higgins, A ;
Landesman, S ;
Moroso, G ;
Willoughby, A ;
Sheon, A ;
McKinlay, S ;
Sherrieb, K .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1207-1211
[8]  
DEMMLER GJ, 1991, REV INFECT DIS, V13, P8
[9]  
FISCUS SA, 1996, JAMA-J AM MED ASSOC, V275, P1514
[10]   Infection of primary CD4(+) and CD8(+) T lymphocytes by Epstein-Barr virus enhances human immunodeficiency virus expression [J].
Guan, MX ;
Zhang, RD ;
Wu, B ;
Henderson, EE .
JOURNAL OF VIROLOGY, 1996, 70 (10) :7341-7346